Crixivan Related Published Studies
Well-designed clinical trials related to Crixivan (Indinavir)
Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. [2008.03.01]
Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. [2008.01]
Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Cote d'Ivoire. [2007.01]
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. [2006.08.01]
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). [2006]
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). [2006]
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. [2005.09]
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. [2005.08]
Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. [2005.07.01]
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073). [2005.06]
A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. [2005.04.12]
Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. [2005.03]
Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. [2005.02]
Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial. [2004.12]
Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. [2004.12]
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. [2004.11.01]
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. [2004.11]
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. [2004.08.01]
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. [2004.07]
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). [2004.07]
Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). [2004.04]
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. [2004.03.15]
Indinavir and rifabutin drug interactions in healthy volunteers. [2004.03]
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. [2003.12]
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. [2003.11.07]
[A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir] [2003.10.25]
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. [2003.10.15]
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. [2003.09.01]
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. [2003.08]
Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. [2003.07]
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. [2003.06]
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. [2003.05.23]
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. [2003.04.11]
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. [2003.03]
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. [2003.01]
Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. [2003.01]
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. [2002.12.15]
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1. [2002.11.01]
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). [2002.06]
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. [2002.03.29]
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. [2002.03.08]
Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. [2002.02]
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. [2001.12.04]
Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). [2001.12]
Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. [2001.10]
Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. [2001.04]
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. [2001.03.07]
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. [2001.03]
Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. [2001.02.01]
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. [2001.01]
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. [2001]
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. [2000.12.22]
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. [2000.11.20]
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. [2000.09.08]
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. [2000.09]
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). [2000.07.28]
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). [2000.07.28]
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. [2000.07.28]
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. [2000.07.04]
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. [2000.06.16]
The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. [2000.04]
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients. [2000.01.28]
Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. [2000.01]
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. [1999.12.16]
Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir. [1999.10]
The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial. [1999.10]
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. [1999.09]
Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects. [1999.06]
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). [1999.05.07]
Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. [1999.05]
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. [1998.10.29]
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. [1998.07.01]
Single-dose pharmacokinetics of indinavir and the effect of food. [1998.02]
Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. [1998.02]
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. [1997.09.11]
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. [1997.09.11]
Well-designed clinical trials possibly related to Crixivan (Indinavir)
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. [2008.08.15]
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. [2008.01]
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. [2008.01]
Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. [2007.02]
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. [2007.01.24]
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). [2006.06]
Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. [2006.04.01]
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection] [2006.02]
Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. [2006]
Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. [2005.12.01]
The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. [2005.09.02]
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081). [2005.03.01]
Gender differences in health-related quality of life in patients with HIV/AIDS. [2005.03]
Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. [2004.11]
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. [2004.02]
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). [2004.01]
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. [2003.12.05]
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. [2003.09.01]
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. [2003.08.19]
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. [2003.05.02]
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. [2002.12.06]
Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. [2002.10]
Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. [2002.09]
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. [2002.07.10]
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. [2002.06]
|
